奥希替尼 T2490
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
TargetMol | 生产商 | 美国 | 现货 |
性能特点
生化试剂,可用于动物细胞实验
规格 | CAS号 | 价格 | 操作 |
---|---|---|---|
500 mg | 1421373-65-0 | ¥4,730.00 | 询底价 |
1 g | 1421373-65-0 | ¥6,490.00 | 询底价 |
1 mg | 1421373-65-0 | ¥198.00 | 询底价 |
5 mg | 1421373-65-0 | ¥473.00 | 询底价 |
50 mg | 1421373-65-0 | ¥1,230.00 | 询底价 |
200 mg | 1421373-65-0 | ¥2,570.00 | 询底价 |
2 mg | 1421373-65-0 | ¥283.00 | 询底价 |
10 mg | 1421373-65-0 | ¥653.00 | 询底价 |
100 mg | 1421373-65-0 | ¥1,660.00 | 询底价 |
1 mL | 1421373-65-0 | ¥535.00 | 询底价 |
25 mg | 1421373-65-0 | ¥987.00 | 询底价 |
Product Introduction
Bioactivity
英文名: Osimertinib
描述: Osimertinib (AZD-9291) 是一种 EGFR 三代抑制剂,抑制二代 EGFR 抑制剂产生的 T790M 耐药突变,具有不可逆性和口服活性。Osimertinib 具有抗肿瘤活性,用于治疗 EGFR 突变的非小细胞肺癌。
细胞实验: AZD-9291 is dissolved in DMSO and stored, and then diluted with appropriate medium before use[1]. PC-9 cells are seeded into T75 flasks (5×105 cells/flask) in RPMI growth media and incubated at 37°C, 5% CO2. The following day the media is replaced with media supplemented with a concentration of EGFR inhibitor equal to the EC50 concentration predetermined in PC-9 cells. Media changes are carried out every 2-3 days and resistant clones allowed to grow to 80% confluency prior to the cells being trypsinised and reseeded at the original seeding density in media containing twice the concentration of EGFR inhibitor. Dose escalations are continued until a final concentration of 1.5 μM Gefitinib, 1.5 μM Afatinib, 1.5 μM WZ4002 or 160 nM AZD-9291 are achieved[1].
激酶实验: ACY-1215 is dissolved and subsequently diluted in assay buffer [50 mM HEPES, pH 7.4, 100 mM KCl, 0.001% Tween-20, 0.05% BSA, and 20 μM tris(2-carboxyethyl)phosphine] to 6-fold the final concentration. HDAC enzymes are diluted to 1.5-fold of the final concentration in assay buffer and pre-incubated with ACY-1215 for 10 minutes before the addition of the substrate. The amount of FTS (HDAC1, HDAC2, HDAC3, and HDAC6) or MAZ-1675 (HDAC4, HDAC5, HDAC7, HDAC8, and HDAC9) used for each enzyme is equal to the Michaelis constant (Km), as determined by a titration curve. FTS or MAZ-1675 is diluted in assay buffer to 6-fold the final concentration with 0.3 μM sequencing grade trypsin. The substrate/trypsin mix is added to the enzyme/compound mix and the plate is shaken for 60 seconds and then placed into a SpectraMax M5 microtiter plate reader. The enzymatic reaction is monitored for release of 7-amino-4-methoxy-coumarin over 30 minutes, after deacetylation of the lysine side chain in the peptide substrate, and the linear rate of the reaction is calculated[1].
体外活性: 方法:人非小细胞肺癌细胞 PC-9 (exon 19del)、H3255 (L858R)、PC-9ER (exon 19del+T790M) 和 H1975 (L858R+T790M) 用 Osimertinib (0.0001-10 µmol/L) 处理 72 h,使用 MTS 方法检测细胞生长抑制情况。结果:Osimertinib 剂量依赖诱导 PC-9、H3255、PC-9ER 和 H1975 细胞生长,IC50 分别为 41、26、41 和 31 nM。[1]方法:EGFR 突变的人非小细胞肺癌细胞 PC-9、H1975、H1650 和 H3255 用 Osimertinib (0.1-1000 nM) 处理 6 h,使用 Western Blot 方法检测靶点蛋白表达水平。结果:Osimertinib 抑制 EGFR 突变肿瘤细胞的 pEGFR(Y1068)、pERK(P-p44/42)、pAKT(S473)。[2]方法:人非小细胞肺癌细胞 NCI-H1975 用 Osimertinib (10-100 nM) 处理 24 h,然后用 2-20 Gy 的剂量照射,使用 Flow Cytometry 方法分析细胞周期情况。结果:联合治疗组 G2/M 和 S 期细胞比例呈剂量依赖性降低。Osimertinib 减少照射后 G2/M 期细胞周期停滞。[3]
体内活性: 方法:为检测体内抗肿瘤活性,将 Osimertinib (5-10 mg/kg) 口服给药给携带人肺癌肿瘤 H1975、PC9 和 A431 的 SCID 小鼠,每天一次,持续七天。结果:Osimertinib 治疗显著抑制 H1975、PC9 和 A431 肿瘤的生长,表明在体内具有抗肿瘤活性。[4]方法:为检测体内抗肿瘤活性,将 Osimertinib (6 mg/kg) 口服给药给用 PC-9/ffluc 细胞构建软脑膜癌病 (LMC) 模型的 SHO-SCID 小鼠,每天一次,持续五十天。结果:Osimertinib 治疗明显延缓了 LMC 的发展。第三代 EGFR-TKI Osimertinib 可能是由 EGFR 突变型肿瘤引起的第一代或第二代 EGFR-TKI 耐药性 LMC 的有效治疗方法。[5]
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: Ethanol : 22 mg/mL(44 mM)
DMSO : 55 mg/mL (110.09 mM)
5% DMSO+95% Saline : 4.6 mg/mL (9.21 mM, suspension)
H2O : < 1 mg/mL (insoluble or slightly soluble)
关键字: AZD 9291 | Inhibitor | Ba/F3 cells | Osimertinib | H1975 | EGFR | PC-9 | tumor xenograft model | ErbB-1 | AZD9291 | HER1 | inhibit | cancer | Epidermal growth factor receptor
相关产品: EGFR-IN-61 | Nuvenzepine | KI8751 | Lazertinib | Tyrphostin AG30 | AZD3759 hydrochloride | Gefitinib-based PROTAC 3 | Pyrotinib dimaleate | Rilematovir | Desmethyl Erlotinib
相关库: Drug Repurposing Compound Library | FDA-Approved Kinase Inhibitor Library | Anti-Cancer Drug Library | Inhibitor Library | Anti-Cancer Clinical Compound Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Approved Drug Library | Anti-Cancer Active Compound Library | Highly Selective Inhibitor Library | EMA Approved Drug Library
奥希替尼 T2490信息由TargetMol中国为您提供,如您想了解更多关于奥希替尼 T2490报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途